New Zealand markets closed

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
422.78+3.79 (+0.90%)
At close: 04:00PM EDT
423.40 +0.62 (+0.15%)
After hours: 07:41PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 109.10B
Enterprise value 99.65B
Trailing P/E 27.44
Forward P/E 26.11
PEG ratio (5-yr expected) 0.57
Price/sales (ttm)10.82
Price/book (mrq)5.88
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.39
52-week change 321.26%
S&P500 52-week change 326.27%
52-week high 3448.40
52-week low 3320.01
50-day moving average 3407.92
200-day moving average 3386.02

Share statistics

Avg vol (3-month) 31.04M
Avg vol (10-day) 31.22M
Shares outstanding 5258.05M
Implied shares outstanding 6258.05M
Float 8257.31M
% held by insiders 10.11%
% held by institutions 197.76%
Shares short (30 Apr 2024) 43.87M
Short ratio (30 Apr 2024) 44.02
Short % of float (30 Apr 2024) 41.50%
Short % of shares outstanding (30 Apr 2024) 41.50%
Shares short (prior month 28 Mar 2024) 43.98M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 22:1
Last split date 324 Aug 2000

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 39.46%
Operating margin (ttm)45.20%

Management effectiveness

Return on assets (ttm)12.82%
Return on equity (ttm)24.38%

Income statement

Revenue (ttm)10.18B
Revenue per share (ttm)39.49
Quarterly revenue growth (yoy)13.30%
Gross profit (ttm)N/A
EBITDA 4.58B
Net income avi to common (ttm)4.02B
Diluted EPS (ttm)15.39
Quarterly earnings growth (yoy)57.10%

Balance sheet

Total cash (mrq)10.17B
Total cash per share (mrq)39.42
Total debt (mrq)721.3M
Total debt/equity (mrq)3.89%
Current ratio (mrq)3.50
Book value per share (mrq)71.80

Cash flow statement

Operating cash flow (ttm)3.94B
Levered free cash flow (ttm)3.31B